AAS Protect

Aspirin

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of AAS Protect

Property	Description
Active Ingredient	Acetylsalicylic Acid (ASA) (Aspirin)
Form	Enteric-coated tablet (Oral)
Pharmacological Class	Antiplatelet agent; Non-steroidal anti-inflammatory drug (NSAID)
Common Purpose	Maintaining smooth blood flow; relieving minor pain/swelling
Origin	Synthetic (Salicylate derivative)

What is AAS Protect and its Core Identity?

AAS Protect is a single-ingredient pharmaceutical preparation whose active ingredient is Acetylsalicylic Acid (ASA), internationally recognized as Aspirin. This medication is a Salicylate derivative of purely synthetic origin, delivered as an oral dosage form, specifically an enteric-coated tablet. This chemical entity is one of the most widely studied compounds, and its properties are fully documented. This confirms the fundamental identity of the substance at the core of the preparation. AAS Protect is typically positioned in the market as an over-the-counter (OTC) medicine focused on cardiovascular health.

Classification: Is AAS Protect an NSAID or an Antiplatelet Agent?

AAS Protect holds a dual classification, functioning primarily as an Antiplatelet agent while also belonging to the broader category of Non-steroidal anti-inflammatory drugs (NSAIDs). This dual nature is crucial because the drug's defining characteristic is its specialized antiplatelet action, which helps prevent blood platelets from clumping together. Unlike other NSAIDs like ibuprofen, which are often used only for pain and fever, AAS Protect's mechanism emphasizes its role as an anti-thrombotic agent to maintain smooth blood flow. The primary antiplatelet use of low-dose aspirin is focused on preventing blood flow issues. The medication is clinically recognized for its ability to help keep blood flowing smoothly.

General Purpose and the Benefit of its Specialized Form

The overall objective of AAS Protect is to support the maintenance of smooth blood flow and provide high-level relief for minor aches and mild swelling by modifying key signaling pathways in the body. The specific enteric-coated tablet form is designed with a specialized coating to ensure the Acetylsalicylic Acid remains intact in the acidic environment of the stomach. This feature is integral to the product's identity, as it facilitates proper drug absorption by dissolving later in the intestinal tract and minimizes direct irritation to the stomach lining, which is a recognized benefit of this particular formulation type.

What side effects are possible with AAS Protect?

Possible Side Effects and Safety Information

The safety profile of AAS Protect is established through formal documents from government regulatory authorities (such as the FDA, EMA, and Health Canada) which classify adverse reactions by affected body system and frequency of occurrence.

Key Adverse Reaction Categories

Adverse reactions are formally grouped into System-Organ-Class Safety Groups (e.g., Gastrointestinal disorders, Nervous system disorders) and listed according to a Frequency Classification (e.g., Common, Uncommon, Rare) based on data from clinical studies and post-market surveillance.

Serious Adverse Reactions: Official documents highlight the risk of Serious Adverse Drug Reactions (ADRs). These are defined as events that may be life-threatening, result in death, require or prolong hospitalization, or cause persistent disability. Serious reactions include stomach bleeding, ulceration, and significant allergic responses.
Dose- or Exposure-Related Patterns: The risk of bleeding, particularly gastrointestinal bleeding, is noted to be increased with concurrent use of alcohol or other blood thinning agents. The occurrence of ringing in the ears (tinnitus) is explicitly listed as a potential effect associated with high doses.

Population-Specific Safety Restrictions

Official safety documents define specific restrictions for certain patient populations where the risk is formally documented to be higher:

Children and Teenagers: Use of this medicine is generally restricted in children and teenagers who have or are recovering from viral illnesses like flu or chickenpox due to the formal regulatory warning about the risk of Reye syndrome, a rare but serious condition.
Pregnancy and Elderly: Use is not recommended in the last part of pregnancy. Caution is formally advised for use in the elderly, as the safety risk profile is noted to be greater in older individuals.

Regulatory Safety Summary

The official safety structure mandates the mandatory and timely reporting of all serious adverse events to government authorities. This framework ensures that the full spectrum of known side effects, their likelihood, and specific high-risk conditions are clearly documented. The safety information structures the understanding of risks by detailing the most critical concerns (Serious ADRs) and specifying patient groups where known risks are heightened (e.g., Reye syndrome risk).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Acetylsalicylic Acid (AAS Protect) by its manifestations and required emergency actions.

Documented Overdose Manifestations

Symptoms of mild-to-moderate overdose, or salicylism, typically include tinnitus (ringing in the ears), hearing impairment, nausea, vomiting, and hyperventilation (rapid breathing). Severe intoxication is associated with more critical manifestations, including metabolic acidosis, seizures, coma, cardiovascular collapse, and pulmonary edema.

Emergency Actions Mandated by Regulators

Action Required	Official Regulatory Statement
Immediate Help	Seek immediate medical attention for any suspected overdose. Call emergency services (e.g., 911) or contact a Poison Control Center for guidance.
Antidote	No specific antidote is known for salicylate poisoning.
Management	Management is primarily symptomatic and supportive, and may include procedures like activated charcoal, urinary alkalinization, or hemodialysis for severe cases.
Monitoring	Hospitalization and close observation are required, including continuous monitoring of serum salicylate concentrations and acid-base balance (ABGs).

Regulatory documents also note specific populations have increased risk, stating that children have a higher susceptibility to toxicity and elderly patients or those with existing renal/hepatic impairment may be more prone to severe outcomes.

Therapeutic Uses of AAS Protect

What AAS Protect Treats: Main Uses and Benefits

The core therapeutic function of AAS Protect is applied across key therapeutic domains where additional symptomatic support is needed, primarily addressing both long-term cardiovascular risk and acute discomfort. The medication is used for reducing fever, relieving mild to moderate pain, and preventing heart attacks and strokes.

Reducing Risk of Vascular Events in High-Risk Patients

This domain focuses on long-term therapeutic support generally provided to individuals with established cardiovascular disease or those at high risk. The medicine is commonly used to help with reducing the long-term risk of a heart attack or ischemic stroke. This use contributes to easing the overall symptom load related to cardiovascular risk management. This use is relevant in conditions presenting with systemic or localized discomfort associated with vascular risk.

“This supportive use provides assistance with maintaining blood flow, particularly in individuals with documented vascular issues.”

Quick Fact: Relief for Vascular Risk Management

Easing Acute Pain, Fever, and Inflammatory Symptoms

This usage targets episodic symptomatic discomfort. The medication is commonly used to help with acute symptomatic episodes marked by generalized pain, such as headache and muscle aches, elevated body temperature (fever) associated with minor illnesses, and localized swelling linked to inflammatory conditions. This support helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. The medication is applied when appropriate for supportive symptom management.

Regulatory References

NIH MedlinePlus overview of Aspirin

Eligibility and Restrictions for Use

Official Regulatory Eligibility for AAS Protect

This section outlines the officially documented population eligibility and non-eligibility rules for the medicine, as defined in government regulatory documents.

Category	Eligibility Status (Regulatory Wording)
Absolute Contraindications	Hypersensitivity to Acetylsalicylic Acid (ASA) or other NSAIDs, severe hepatic or renal failure, active or history of recurrent peptic ulcer/gastrointestinal hemorrhage, severe heart failure, or a hemorrhagic diathesis.
Pregnancy Eligibility	Contraindicated in the third trimester. Use is not recommended between 20 and 30 weeks gestation due to fetal risk. Lactation is generally not recommended.
Pediatric Eligibility	Not recommended for general use in individuals under 16 years. Contraindicated in children and adolescents with suspected viral illness due to the risk of Reye's Syndrome.
Conditional Use (Caution)	Use requires caution in older adults, and patients with moderate hepatic or renal impairment, uncontrolled hypertension, or a history of specific gastrointestinal diseases.

The eligibility profile is strictly governed by regulatory documents that define clear constraints based on patient health status and age. Absolute non-eligibility is mandated by severe organ failure, specific bleeding risks, and documented NSAID hypersensitivity. For other populations, such as older adults or those with moderate impairment, use is permitted but officially labeled as requiring caution.

What should I know about interactions with other medicines?

AAS Protect Interactions with Other Medicines and Products

The interaction profile of AAS Protect (Acetylsalicylic Acid, ASA) is officially structured around documented risks that lead to specific constraints on co-administration, as defined in regulatory documents.

Officially Documented Interaction Classifications

Interaction Domain	Practical Regulatory Implication
Pharmacodynamic Reinforcement	Leads to contraindicated combinations with certain Oral Anticoagulants and an increased risk of hemorrhage when co-administered with other Antiplatelet Agents or SSRI antidepressants.
Metabolic and Excretion Interference	Results in officially documented decreased renal clearance for substances like Methotrexate (at doses ge 15 mg/week) and Lithium, potentially increasing their plasma exposure.
Antagonism of Therapeutic Effect	ASA reduces the action of Uricosurics (e.g., Probenecid) due to officially documented competition for elimination in the renal tubules.
GI Toxicity Enhancement	Alcohol and other NSAIDs are officially documented to enhance the risk of gastrointestinal bleeding and ulceration, necessitating caution or prohibition in high-risk patients.

Population and Timing Constraints

Regulatory labels require a formal consultation on the timing of doses for co-administration with Ibuprofen to avoid interfering with the antiplatelet benefit of ASA. Furthermore, specific constraints apply to populations, including an officially documented increased hemorrhage risk for the elderly co-administering Low Molecular Weight Heparins (LMWHs). The official association with Reye’s Syndrome dictates use restrictions in children and adolescents during viral illness.

Mechanism of Action

AAS Protect's mechanism of action is based on its role as an irreversible enzyme inhibitor within the arachidonic acid cascade.

Targeting Prostaglandin Synthesis

AAS Protect acts within the domain of cyclooxygenase (COX) enzyme-mediated signaling. It works by covalently and irreversibly acetylating a specific serine residue in the active site of the COX enzyme, primarily COX-1. This action modifies the early molecular steps of the pathway, suppressing the synthesis of pro-inflammatory prostaglandins and other prostanoids. The resulting physiological effect contributes to the modulation of prostanoid-driven signaling pathways, altering the downstream systemic response.

Modulating Platelet Activity

The drug engages mechanisms that regulate the activity of platelets in the vascular system. By irreversibly inhibiting COX-1 in platelets (which lack the ability to synthesize new enzyme), AAS Protect drastically reduces the formation of thromboxane A2 ( TXA2). TXA2 is a mediator of platelet aggregation and vasoconstriction. This results in a predictable physiological adjustment characterized by the reduction of TXA2-mediated signaling, thereby lowering the propensity of platelets to aggregate.

Dosage and Administration Information

Administration Guidelines

AAS Protect (Acetylsalicylic Acid, ASA) is for oral administration using approved dosage forms such as tablets, caplets, or chewable tablets. Use must strictly adhere to the dosing and procedural instructions provided for the medication.

Instruction Classification	Guideline
Route of Administration	Oral
Standard Dosing	Take the smallest effective unit dose (e.g., 325 mg or 500 mg). Adults and children 12 years and older follow the adult dosing schedule.
Frequency and Timing	Take one dose every 4 to 6 hours as needed. Do not exceed a total daily dose of 4000 mg in 24 hours.
Administration Conditions	Non-effervescent forms must be taken with a full glass of water or milk to aid administration. Effervescent tablets must be fully dissolved in a glass of water before consumption.
Age-Group Rules	For children and teenagers under 18 with flu-like symptoms or chickenpox, a physician or pharmacist must be consulted before use.
Missed Dose Rule	If a regularly scheduled dose is missed, take it as soon as remembered; however, if it is almost time for the next scheduled dose, skip the missed one. Do not take a double dose.

Procedural Structure Summary

The guidelines mandate a specific, procedural structure for use: selecting the smallest required dose, ensuring proper preparation (such as dissolving effervescent tablets), and adhering strictly to the 4-to-6-hour interval. This framework, reinforced by the absolute maximum daily dose, defines the medicine's correct consumption pattern. Adherence to the Administration Conditions is part of the usage protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for AAS Protect

Evidence Base for Vascular Risk Management

Research for AAS Protect was studied for outcomes related to systemic or functional imbalance using large-scale Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies examined outcomes related to systemic or functional imbalance in individuals who had experienced a prior vascular event. Research has been conducted in adults who already had established atherosclerotic cardiovascular disease (ASCVD), including populations with co-existing Diabetes and Hypertension.

Studies monitored major clinical endpoints, such as the incidence of heart attack, nonfatal stroke, and vascular death. These studies were evaluated in populations presenting with conditions characterized by fluctuating or episodic manifestations following a prior vascular event. Long-term follow-up durations were observed in key trials and meta-analyses, often spanning several years, to track outcomes over time.

Studies on Ischemic Events and Mortality

Studies report how outcomes evolved in the observed populations and research examined changes in the occurrence of nonfatal heart attacks and nonfatal strokes. Findings describe patterns observed in these large studies that contribute to understanding symptom patterns related to major health events. These research efforts also concurrently studies monitored outcomes was associated with major bleeding events.

Evidence Base for Acute Symptom Relief

The research for AAS Protect was studied for outcomes related to physical discomfort; the evidence was explored in short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials was evaluated in the general adult population experiencing common symptoms.

Short-Term Outcomes and Onset of Action

Trials report how symptoms evolved in the observed populations over brief periods following administration. Researchers studied time-to-relief measurements, describing patterns related to how quickly a change in discomfort or fever was observed in the study participants. Follow-up durations for these studies were limited, typically lasting only hours or a few days.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about AAS Protect (FAQ)

Q: What is AAS Protect?

A: AAS Protect is a medication containing acetylsalicylic acid (ASA), also known as Aspirin, and the proton pump inhibitor omeprazole. It is used to help prevent serious cardiovascular events (like heart attack or stroke) in certain patients who are at risk, while also helping to reduce the risk of stomach and intestinal ulcers that can be caused by the long-term use of ASA.

Q: How does AAS Protect work?

A: AAS Protect has a dual action:

Acetylsalicylic acid (ASA) works by reducing the stickiness of platelets (a type of blood cell). This prevents platelets from clumping together and forming blood clots that can block arteries, which helps to prevent heart attacks and strokes.
Omeprazole works by reducing the amount of acid produced in the stomach. This helps to protect the stomach lining and reduces the risk of developing ulcers or bleeding, which is a common side effect of long-term ASA use.

Q: Who should take AAS Protect?

A: AAS Protect is typically prescribed for patients who need to take low-dose aspirin long-term for the prevention of cardiovascular events (secondary prevention) AND who are considered to be at an increased risk of developing gastrointestinal ulcers or bleeding. Your doctor will determine if this medication is appropriate for your specific health situation.

Q: When should I take AAS Protect?

A: You should take AAS Protect exactly as your doctor prescribed. It is usually taken once a day. You may take it with or without food, but it should be swallowed whole with a glass of water. Do not crush, chew, or split the capsule as this will affect how the medication works. Try to take it at the same time each day to help you remember.

Q: What are the common side effects of AAS Protect?

A: Common side effects can include:

Stomach discomfort or pain
Indigestion or heartburn
Nausea
Diarrhea or constipation
Headache

If you experience persistent or severe side effects, you should speak with your doctor.

Q: Can I take other pain relievers with AAS Protect?

A: You should consult your doctor before taking any other pain relievers or non-prescription medications while on AAS Protect. Taking other nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen can increase the risk of bleeding and stomach ulcers. Acetaminophen (paracetamol) is generally considered a safer alternative for pain relief, but you should still confirm with your healthcare provider.

Q: What if I miss a dose of AAS Protect?

A: If you miss a dose, take it as soon as you remember. However, if it is less than 12 hours before your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

Q: How long will I need to take AAS Protect?

A: AAS Protect is often prescribed as a long-term therapy for chronic cardiovascular risk management. The duration of treatment will depend on your specific medical condition and your doctor’s assessment of your ongoing risk of cardiovascular events and gastrointestinal side effects. Do not stop taking the medication without first consulting your doctor.

Q: Does AAS Protect cure heart disease?

A: No, AAS Protect is used to help prevent serious cardiovascular events like heart attacks and strokes by reducing the risk of blood clots. It is not a cure for underlying heart disease. It is part of a broader treatment plan that may include lifestyle changes and other medications recommended by your doctor.

How should AAS Protect be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal requirements for AAS Protect (Acetylsalicylic Acid) are based strictly on regulatory labeling to maintain quality and safety.

Domain	Regulatory Requirement
Temperature	Store at controlled room temperature (e.g., 20 C to 25 C).
Protection	Must be protected from moisture and kept in a tightly closed container; avoid excessive heat.
Stability Check	Discard immediately if the product develops a strong vinegar-like odor (signaling decomposition).
Child Safety	Mandatory to keep the medication out of the reach of children.
Disposal	Dispose of unused product in accordance with national and local regulations, favoring official medicine take-back programs over household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Brazil

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z